Charles River Laboratories CRL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's total liabilities & equity?
- Charles River Laboratories (CRL) reported total liabilities & equity of $7.73B in Q1 2026.
- How has Charles River Laboratories's total liabilities & equity changed year-over-year?
- Charles River Laboratories's total liabilities & equity increased by 2.0% year-over-year, from $7.58B to $7.73B.
- What is the long-term trend for Charles River Laboratories's total liabilities & equity?
- Over 5 years (2020 to 2025), Charles River Laboratories's total liabilities & equity has grown at a 5.4% compound annual growth rate (CAGR), from $5.49B to $7.14B.
- What does total liabilities & equity mean?
- The total value of all money owed to others plus the total value belonging to shareholders.
- How do you interpret total liabilities & equity?
- An increase reflects growth in the company's asset base financed through debt or equity, while a decrease may indicate asset liquidation or deleveraging.
- How does total liabilities & equity compare across companies?
- Standardized across all public companies as the total balance sheet size.